-+ 0.00%
-+ 0.00%
-+ 0.00%

Beyond Cancer posts updated Phase 1 UNO survival data at AACR 2026

PUBT·04/20/2026 12:06:31
Listen to the news
Beyond Cancer posts updated Phase 1 UNO survival data at AACR 2026
  • Beyond Cancer, Beyond Air unit, reported updated Phase 1 follow-up for intratumoral UNO presented at AACR 2026.
  • Six of 10 heavily pretreated patients were alive 22 to 40 months after a single UNO injection as of Feb. 2, 2026.
  • Median overall survival was not reached at last follow-up because more than 50% of patients remained alive.
  • Safety profile was generally favorable; one treatment-related serious adverse event, hypoxia, resolved fully.
  • Beyond Cancer received a US Notice of Allowance for a patent covering gas delivery technology for UNO.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Air Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604200800PRIMZONEFULLFEED9692446) on April 20, 2026, and is solely responsible for the information contained therein.